17890-64-1

Upstream product

• 925-90-6 ethylmagnesium bromide 
• 119-36-8 methyl salicylate 
• 118-61-6 2-hydroxy-benzoic acid ethyl ester 
• 74-96-4 ethyl bromide 

Downstream Products

• 10277-99-3 2-(1-ethyl-propenyl)-phenol 
• 27507-92-2 2-(4-chloro-phenyl)-4,4-diethyl-4H-benzo[e][1,3]oxazine 
• 17890-68-5 N-Acetyl-α,α-diaethyl-o-hydroxy-benzylamin 
• 17890-69-6 α,α,N-Triaethyl-o-hydroxy-benzylamin 
• 80751-97-9 o-(1-ethylpropyl)phenol 
• 55709-93-8 2-Diethylaminomethyl-4,4-diethyl-4H-1,3-benzoxazine hydrochloride 
• 27412-20-0 2-benzyl-4,4-diethyl-4H-benzo[e][1,3]oxazine 

Relevant academic research and scientific papers

Improved Synthesis of MediPhos Ligands and Their Use in the Pd-Catalyzed Enantioselective N-Allylation of Glycine Esters

A new class of chiral C2-symmetric diphosphines (MediPhos) was recently shown to give superior results in the Pd-catalyzed asymmetric N-allylation of amino acid esters. We here describe a new, improved protocol for the preparation of such ligands through bidirectional SN2-coupling of a tartrate-derived ditosylate with 6-alkyl-2-bromophenols followed by double lithiation/phosphanylation. This method gave access to a series of nine ligands with branched alkyl substituents, which were benchmarked in the enantioselective Pd-catalyzed N-allylation of tert-butyl glycinate with racemic (E)-2,8-dimethylnona-5-en-4-yl methyl carbonate (up to 95 % ee). In addition, the analogous transformation of tert-butyl glycinate with methyl (E)-nona-5-en-4-yl carbonate was optimized. The obtained allylic amines were then used in the stereoselective synthesis of the conformationally restricted proline-derived dipeptide analogs ProM-17 and ProM-21.

Vitamin D analogues

The invention relates to compounds of formula I STR1 in which formula X is hydrogen or hydroxy; Y is oxygen, sulphur, or oxidized sulfur (S(O) or S(O2)); R1 and R2, which may be the same or different, stand for hydrogen or C1 -C6 hydrocarbyl, or R1 and R2, taken together with the carbon atom (starred in formula I) bearing the group X, form a C3 -C8 carbocyclic ring; Q is a C1 -C8 hydrocarbylene diradical. R3 is hydrogen or C1 -C6 hydrocarbyl. R1, R2 and/or Q, may be optionally substituted with one or more deuterium or fluorine atoms; n is 0 or 1. The present compounds show antiinflammatory and immunomodulating effects as well as a strong activity in inducing cell differentiation and inhibiting undesirable proliferation of certain cancer and skin cells.